Your browser doesn't support javascript.
Interferon-α2b induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study.
Li, Xina; Liu, Tong; Hai, Xin; Li, Le.
  • Li X; Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Liu T; Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.
  • Hai X; Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Li L; Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Immunopharmacol Immunotoxicol ; 43(6): 644-650, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1545788
ABSTRACT

BACKGROUND:

The current outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread throughout the world. During treatment, we found that the majority of patients had a decrease in hemoglobin (Hb). Interferon-α2b (IFN-α2b) was the primary suspected drug that was related to Hb reduction. Thus, the study aimed to investigate whether IFN-α2b could induce Hb reduction in severe patients with COVID-19 and its potential mechanism. MATERIAL AND

METHODS:

A total of 50 patients who were admitted to the First Affiliated Hospital of Harbin Medical University with severe COVID-19 infection were enrolled from February 12th to 24th, 2020. The demographics, baseline characteristics, clinical data, and therapeutic regimen were collected retrospectively. The patients were divided into two groups according to the declined use of IFN-α2b on day 14. The Hb levels on admission, day 7, day14, and day 21 were collected and analyzed. The primary endpoint was the level of Hb on day 21.

RESULTS:

A total of 31 patients in the IFN-stop group and 19 patients in the non-IFN-stop group were reviewed. The age, gender, comorbidities, clinical symptoms, nutritional status, disease severity, complications, and other factors of the patients were compared, no difference was found between the IFN-stop group and the non-IFN-stop group. The Hb levels of all patients significantly decreased on day 7 compared with that on admission (p < .0001). In the IFN-stop group, the Hb level was increased in 7 days after IFN-α2b was stopped (p = .0008), whereas no difference was found between day 14 and day 21 in the non-IFN-stop group (p = .3152).

CONCLUSIONS:

IFN-α2b was associated with Hb reduction in the treatment of severe patients of COVID-19. Clinicians should be aware of the high incidence of Hb reduction for patients treated by IFN-α2b.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Interferon alpha-2 / SARS-CoV-2 / COVID-19 Drug Treatment / Anemia Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Immunopharmacol Immunotoxicol Journal subject: Allergy and Immunology / Pharmacology / Toxicology Year: 2021 Document Type: Article Affiliation country: 08923973.2021.1992634

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Interferon alpha-2 / SARS-CoV-2 / COVID-19 Drug Treatment / Anemia Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Immunopharmacol Immunotoxicol Journal subject: Allergy and Immunology / Pharmacology / Toxicology Year: 2021 Document Type: Article Affiliation country: 08923973.2021.1992634